Skip to content
Advertisement

A sign for the Food and Drug Administration is displayed outside their offices in Silver Spring, Md., on Dec. 10, 2020. On Tuesday, April 25, 2023, the FDA approved tofersen, a first-of-a-kind drug for a rare form of Lou Gehrig’s disease, though they are requiring further research to confirm it truly helps patients. Biogen will sell the drug under the brand name Qalsody. (AP Photo/Manuel Balce Ceneta, File)

A sign for the Food and Drug Administration is displayed outside their offices in Silver Spring, Md., on Dec. 10, 2020. On Tuesday, April 25, 2023, the FDA approved tofersen, a first-of-a-kind drug for a rare form of Lou Gehrig’s disease, though they are requiring further research to confirm it truly helps patients. Biogen will sell the drug under the brand name Qalsody. (AP Photo/Manuel Balce Ceneta, File)

Featured Photo Galleries